Cargando…

Payer Perspectives on Health Technology Assessment

Detalles Bibliográficos
Autor principal:	Watkins, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437617/ https://www.ncbi.nlm.nih.gov/pubmed/22468735 http://dx.doi.org/10.18553/jmcp.2012.18.3.265

Ejemplares similares

Pharmaceutical Technology Assessment: Perspectives from Payers
por: Leung, Musetta Y., et al.
Publicado: (2012)

Commentary on “Health Spending Under Single-Payer Approaches”
por: Ginsburg, Paul B.
Publicado: (2020)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)

Assessing payer perspectives on health information exchange
por: Cross, Dori A, et al.
Publicado: (2016)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Sepsis-2.5: Resolving Conflicts Between Payers and Providers
por: Rodenberg, Howard, et al.
Publicado: (2023)

Health Care Leaders’ Perspectives on the Maryland All-Payer Model
por: Kilaru, Austin S., et al.
Publicado: (2022)

Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients
por: Saverno, Kim R., et al.
Publicado: (2012)

The Payer's Dilemma: Recognizing the Uncertainty of Clinical and Economic Evidence at Product Launch
por: Watkins, John B., et al.
Publicado: (2009)

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
por: Binder, Louise, et al.
Publicado: (2022)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Cost-effectiveness of a hybrid emergency room system for severe trauma: a health technology assessment from the perspective of the third-party payer in Japan
por: Kinoshita, Takahiro, et al.
Publicado: (2021)

Blockchains, Formulary Evaluations and Health Technology Assessment
por: Langley, Paul C, et al.
Publicado: (2018)

Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast]
por: Drummond, Michael F, et al.
Publicado: (2022)

Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
por: Molfenter, Todd, et al.
Publicado: (2015)

Impact of a Global Pandemic on Health Technology Assessment
por: Lorgelly, Paula K., et al.
Publicado: (2020)

Some considerations on target estimands for health technology assessment
por: Remiro‐Azócar, Antonio
Publicado: (2022)

Hospitals and the Tax-Payer
Publicado: (1920)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

New Health Technologies: A UK Perspective: Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies"
por: Parvizi, Nassim, et al.
Publicado: (2017)

How new technologies could impact on radiology diagnosis and assessment of pancreatic lesions: Future perspectives
por: Laghi, Andrea, et al.
Publicado: (2018)

PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH
por: Moloney, Rachael, et al.
Publicado: (2015)

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
por: Borse, Rebekah H., et al.
Publicado: (2017)

PREEMPTIVE PHARMACOGENETIC TESTING: EXPLORING THE KNOWLEDGE AND PERSPECTIVES OF UNITED STATES PAYERS
por: Keeling, Nicholas J., et al.
Publicado: (2017)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
por: Pastor-Quirós, Luis J., et al.
Publicado: (2021)

Incremental cost of premature birth – a public health care payer perspective from Hungary
por: Kovács, Gábor, et al.
Publicado: (2023)

The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians
por: Sommariva, Silvia, et al.
Publicado: (2016)

How can health technology assessment support our response to public health emergencies?
por: Ananthakrishnan, Aparna, et al.
Publicado: (2022)

Decisions in health technology assessment: should we speak with one voice?
por: Merlin, Tracy
Publicado: (2018)

If You Build it Will They Come? Patients, Providers and Blockchains in Health Technology Assessment
por: Langley, Paul C, et al.
Publicado: (2018)

Blockchains, Property Rights and Health Technology Assessment in the Pharmaceutical and Device (s) Industries
por: Langley, Paul C, et al.
Publicado: (2018)

The role of Iran's context for the development of health technology assessment: challenges and solutions
por: Behzadifar, Meysam, et al.
Publicado: (2023)

The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling"
por: Kim, Hansoo, et al.
Publicado: (2020)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

Payer perceptions and use of value assessment tools in the United States
por: Westrich, Kimberly, et al.
Publicado: (2023)

NICE Medical Technologies Guidance: A Novel and Rigorous Methodology to Address a New Health Technology Assessment Challenge
por: Campbell, Bruce, et al.
Publicado: (2012)

The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment
por: Langley, Paul C
Publicado: (2020)

After The QALY: Training for a New Start Paradigm in Health Technology Assessment
por: Langley, Paul C, et al.
Publicado: (2023)

Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions: Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling"
por: Zawadzki, Nadine K., et al.
Publicado: (2019)

Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
por: Mills, Mackenzie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kqkr4h2g2vv9ana5o6vue1h6p5